Keros doses first patient in Phase 2 rinvatercept trial for Duchenne muscular dystrophy
Early data from the study are expected in the first half of 2027.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Keros Therapeutics doses first patient in Phase 2 DMD trial
Keros Therapeutics said it has dosed the first patient in a Phase 2 clinical trial evaluating rinvatercept in Duchenne muscular dystrophy.